Next Article in Journal
Glutathione Peroxidase (GPx) and Superoxide Dismutase (SOD) in Oropharyngeal Cancer Associated with EBV and HPV Coinfection
Previous Article in Journal
Going beyond Integration: The Emerging Role of HIV-1 Integrase in Virion Morphogenesis
Open AccessArticle

Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds

1
Division of Infectious Diseases, Stanford University School of Medicine, Stanford, CA 94305, USA
2
Undergraduate School of Humanities and Sciences, Stanford University, Stanford, CA 94305, USA
3
Undergraduate Studies, University of California, Berkeley, CA 94720, USA
4
Data First Consulting Inc., Sebastopol, CA 95472, USA
*
Authors to whom correspondence should be addressed.
Viruses 2020, 12(9), 1006; https://doi.org/10.3390/v12091006
Received: 21 July 2020 / Revised: 29 August 2020 / Accepted: 4 September 2020 / Published: 9 September 2020
(This article belongs to the Section SARS-CoV-2 and COVID-19)
Background: To prioritize the development of antiviral compounds, it is necessary to compare their relative preclinical activity and clinical efficacy. Methods: We reviewed in vitro, animal model, and clinical studies of candidate anti-coronavirus compounds and placed extracted data in an online relational database. Results: As of August 2020, the Coronavirus Antiviral Research Database (CoV-RDB; covdb.stanford.edu) contained over 2800 cell culture, entry assay, and biochemical experiments, 259 animal model studies, and 73 clinical studies from over 400 published papers. SARS-CoV-2, SARS-CoV, and MERS-CoV account for 85% of the data. Approximately 75% of experiments involved compounds with known or likely mechanisms of action, including monoclonal antibodies and receptor binding inhibitors (21%), viral protease inhibitors (17%), miscellaneous host-acting inhibitors (10%), polymerase inhibitors (9%), interferons (7%), fusion inhibitors (5%), and host protease inhibitors (5%). Of 975 compounds with known or likely mechanism, 135 (14%) are licensed in the U.S. for other indications, 197 (20%) are licensed outside the U.S. or are in human trials, and 595 (61%) are pre-clinical investigational compounds. Conclusion: CoV-RDB facilitates comparisons between different candidate antiviral compounds, thereby helping scientists, clinical investigators, public health officials, and funding agencies prioritize the most promising compounds and repurposed drugs for further development. View Full-Text
Keywords: coronavirus; COVID-19; SARS-CoV-2; SARS-CoV; MERS-CoV; antiviral therapy coronavirus; COVID-19; SARS-CoV-2; SARS-CoV; MERS-CoV; antiviral therapy
Show Figures

Figure 1

MDPI and ACS Style

Tzou, P.L.; Tao, K.; Nouhin, J.; Rhee, S.-Y.; Hu, B.D.; Pai, S.; Parkin, N.; Shafer, R.W. Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds. Viruses 2020, 12, 1006. https://doi.org/10.3390/v12091006

AMA Style

Tzou PL, Tao K, Nouhin J, Rhee S-Y, Hu BD, Pai S, Parkin N, Shafer RW. Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds. Viruses. 2020; 12(9):1006. https://doi.org/10.3390/v12091006

Chicago/Turabian Style

Tzou, Philip L.; Tao, Kaiming; Nouhin, Janin; Rhee, Soo-Yon; Hu, Benjamin D.; Pai, Shruti; Parkin, Neil; Shafer, Robert W. 2020. "Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds" Viruses 12, no. 9: 1006. https://doi.org/10.3390/v12091006

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop